AVTX Avalo Therapeutics, Inc.
Healthcare$16.02-2.02%ClosedMarket Cap: $180.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.81
P/S
3129.81
EV/EBITDA
-1.79
DCF Value
$0.99
FCF Yield
-32.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
71.2%
Operating Margin
-134164.4%
Net Margin
-143627.1%
ROE
-97.5%
ROA
-84.8%
ROIC
-89.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-20.9M | $-19.6M | $— | — |
| Q4 null | $59.0K | 100.0% | $-19.7M | $-13.7M | $— | — |
| FY null | $59.0K | 100.0% | $-72.9M | $-78.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-19.2M | $-30.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-19.3M | $-20.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-14.7M | $-13.1M | $— | — |
| Q4 null | $192.0K | 54.7% | $-13.3M | $-35.3M | $— | — |
| FY null | $441.0K | 183.0% | $-68.5M | $-35.1M | $— | — |
| Q3 null | $249.0K | 386.7% | $-12.9M | $23.0M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-9.6M | $98.5M | $— | — |
| Q1 null | $0.00 | Infinity% | $-32.8M | $-121.3M | $— | — |
| Q4 2023 | $571.0K | 138.7% | $-3.8M | $-8.2M | $-10.19 | — |